Physician profile

Julia Isom

Family Medicine · Johns Island, SC

NPI 1093163339

$5,172.16

in general payments reported to CMS, 2019-2025

43 companies · $337 in 2025

The $337 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,768.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $546.09 2019-2024 Fasenra, Airsupra
Novo Nordisk INC $490.32 2019-2025 Rybelsus, Ozempic, Wegovy
Abbvie INC. $350.96 2021-2025
Amarin Pharma, INC. $287.64 2019-2021
Lilly USA, LLC $287.25 2020-2025 Mounjaro, Zepbound, Trulicity
Glaxosmithkline, LLC. $266.91 2020-2025 Shingrix, Arexvy, Boostrix
Amgen INC. $259.53 2019-2021
Pfizer INC. $236.90 2020-2025
Exact Sciences Corporation $234.57 2023-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Boehringer Ingelheim Pharmaceuticals, INC. $213.04 2020-2021
Merck Sharp & Dohme LLC $186.84 2020-2021
Janssen Pharmaceuticals, INC $183.08 2019-2022
Abbott Laboratories $130.40 2023-2025 Freestyle Libre, Freestyle Libre 3, Eterna
Takeda Pharmaceuticals U.S.A., INC. $126.06 2020-2024 Trintellix
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $123.90 2020-2021
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Biohaven Pharmaceuticals, INC. $117.75 2020-2021
Idorsia Pharmaceuticals US INC $112.51 2022-2024 Quviviq
Bayer Healthcare Pharmaceuticals INC. $102.31 2022-2024
Mylan Specialty L.P. $88.12 2020-2024 Yupelri
Allergan, INC. $81.17 2019-2020
Astellas Pharma US INC $75.46 2024 Veozah
Genentech USA, INC. $59.99 2019-2020
Eisai INC. $56.59 2020-2021
Dexcom, INC. $50.46 2024 Dexcom G6 Transmitter
Biogen, INC. $47.96 2020-2023 Skyclarys
Daiichi Sankyo INC. $47.17 2020-2021
Adlon Therapeutics L.P. $46.17 2020-2021
E.R. Squibb & Sons, L.L.C. $42.82 2019-2021
Esperion Therapeutics, INC. $34.10 2021
Sanofi-Aventis U.S. LLC $29.71 2024
Otsuka America Pharmaceutical, INC. $25.30 2023 Nuedexta
Novartis Pharmaceuticals Corporation $25.22 2019-2021
Edwards Lifesciences Corporation $23.90 2023 Edwards Sapien 3 Ultra Transcatheter Heart Valve
Kowa Pharmaceuticals America, INC. $23.71 2019-2020
Supernus Pharmaceuticals, INC. $22.54 2021
Bardy Diagnostics, INC. $22.00 2020
Viatris Specialty LLC $20.85 2025 Yupelri
Alexion Pharmaceuticals, INC. $18.33 2020
Organon LLC $17.70 2025 Nexplanon
Lundbeck LLC $15.66 2023 Rexulti
Boston Scientific Corporation $15.63 2023 Watchman Access System
Hikma Pharmaceuticals USA $13.08 2019
Shire North American Group INC $12.46 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Julia Isom

$5,172.16

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $337 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/1542715/julia-isom

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.